Discover the critical insights on the impact of receiving heart transplants from hepatitis C viremic donors on the development of cardiac allograft vasculopathy in recipients, a key concern in post-transplant care.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Cardiac allograft vasculopathy in heart transplant recipients from hepatitis C viremic donors.
Kadosh et al., Clin Transplant 2024
<!– DOI: 10.1111/ctr.15294 //–>
https://doi.org/10.1111/ctr.15294
This study investigates the impact of using hearts from Hepatitis C viremic donors (NAT+) for transplantation, focusing on the incidence of cardiac allograft vasculopathy (CAV) compared to recipients of non-HCV infected donors (NAT-). Analyzing data from 270 heart transplant recipients, the research found no significant difference in the development of CAV or subclinical intravascular ultrasound (IVUS) disease between the two groups over a three-year period. Specifically, the incidence of CAV at 1, 2, and 3 years post-transplant was slightly lower in the NAT+ group compared to the NAT- group, and after adjusting for various risk factors, NAT+ status did not show an increased risk for CAV or subclinical IVUS disease.
Importance: This study provides evidence supporting the short-term safety of using HCV viremic donor hearts, which could help expand the donor pool and reduce transplant wait times.